Biobank for Inflammatory Chronic Diseases and Osteoporosis
-
- STATUS
- Recruiting
-
- End date
- Sep 1, 2031
-
- participants needed
- 2000
-
- sponsor
- University Hospital, Toulouse
Summary
The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.
Description
Biologic ant targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) have greatly improved the prognosis of chronic inflammatory diseases. To date, many bDMARDs and tsDMARDs targeting different immunologic mechanisms are available to treat RA, SpA or PsA. However, the choice of the treatment and its mechanism of action is based on physician decision and experience. Indeed, predictive clinical and biological factors associated with therapeutic response that could help the physician to make his/her choice are lacking. The aim of BIO-TOUL is to collect and store biologic samples in patients with RA, SpA or PsA who begin a new bDMARD or tsDMARD. This biobank will permit to study several biomarkers and assess the association between such markers and response to therapy.
Furthermore, osteoporosis is a chronic disease leading to fractures and disability. Several ant-osteoporotic drugs are now available and biomarker(s) that would help the physician to choose the best therapeutic sequence are lacking. BIO-TOUL will also include patients with osteoporosis to identify biomarkers associated with severity and response to anti-osteoporotic treatments.
Details
| Condition | Spondylarthritis, spondyloarthritis, Psoriasis, Arthritis, Rheumatoid Arthritis (Pediatric), PSORIATIC ARTHRITIS, Arthritis and Arthritic Pain, Rheumatoid Arthritis, Osteoporosis, Arthritis and Arthritic Pain (Pediatric), Spondyloarthropathy, Psoriasis and Psoriatic Disorders, Osteopenia, Psoriatic Arthritis |
|---|---|
| Treatment | blood sampling |
| Clinical Study Identifier | NCT05039216 |
| Sponsor | University Hospital, Toulouse |
| Last Modified on | 26 September 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer